β-blockers: acting in the brain but healing the heart

References

• Remme WJ. β blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first? Cardiol. Clin.25(4), 581–594 (2007).
   PubMedGoogle Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet353(9146), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Colucci WS, Kolias TJ, Adams KF et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the Reversal Of Ventricular Remodeling With Toprol-XL (REVERT) trial. Circulation116(1), 49–56 (2007).
   PubMedGoogle Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet362(9377), 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B et al.; MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA283(10), 1295–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Nodari S, Metra M, Dei CL. β-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur. J. Heart. Fail.5(5), 621–627 (2003).
   PubMed Web of Science ®Google Scholar
• Weber MA. The role of the new β-blockers in treating cardiovascular disease. Am. J. Hypertens.18, 169S–176S (2005).
   PubMed Web of Science ®Google Scholar
• A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med.344, 1659–1667 (2001).
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on β-adrenergic receptor blockers. Eur. Heart. J.25(15), 1341–1362 (2004).
   PubMed Web of Science ®Google Scholar
• Brodde OE. β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol. Ther.117(1), 1–29 (2008).
   PubMed Web of Science ®Google Scholar
• Shin J, Johnson JA. β-blocker pharmacogenetics in heart failure. Heart. Fail. Rev. DOI: 10.1007/s10741-008-9094-x (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Mialet PJ, Rathz DA, Petrashevskaya NN et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med.9(10), 1300–1305 (2003).
   PubMed Web of Science ®Google Scholar
• Terra SG, Hamilton KK, Pauly DF et al. β1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenet. Genomics15(4), 227–234 (2005).
   PubMedGoogle Scholar
• de Groote P, Helbecque N, Lamblin N et al. Association between β1 and β2 adrenergic receptor gene polymorphisms and the response to β-blockade in patients with stable congestive heart failure. Pharmacogenet. Genomics15(3), 137–142 (2005).
   PubMed Web of Science ®Google Scholar
• White HL, de Boer RA, Maqbool A et al. An evaluation of the β1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart. Fail.5(4), 463–468 (2003).
   PubMed Web of Science ®Google Scholar
• Neil-Dwyer G, Bartlett J, McAinsh J, Cruickshank JM. β-adrenoceptor blockers and the blood–brain barrier. Br. J. Clin. Pharmacol.11(6), 549–553 (1981).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Rosen RC. Central nervous system effects of β-adrenergic-blocking drugs: the role of ancillary properties. Circulation75(1), 204–212 (1987).
   PubMed Web of Science ®Google Scholar
• Parker GW, Michael LH, Hartley CJ, Skinner JE, Entman ML. Central β-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ. Res.66(2), 259–270 (1990).
   PubMed Web of Science ®Google Scholar
• Gourine A, Bondar SI, Spyer KM, Gourine AV. Beneficial effect of the central nervous system β-adrenoceptor blockade on the failing heart. Circ. Res.102(6), 633–636 (2008).
   PubMed Web of Science ®Google Scholar
• Wanaka A, Kiyama H, Murakami T et al. Immunocytochemical localization of β-adrenergic receptors in the rat brain. Brain. Res.485(1), 125–140 (1989).
   PubMedGoogle Scholar
• Nicholas AP, Pieribone VA, Hokfelt T. Cellular localization of messenger RNA for β1- and β2-adrenergic receptors in rat brain: an in situ hybridization study. Neuroscience56(4), 1023–1039 (1993).
   PubMed Web of Science ®Google Scholar
• van Waarde A, Vaalburg W, Doze P, Bosker FJ, Elsinga PH. PET imaging of β-adrenoceptors in human brain: a realistic goal or a mirage? Curr. Pharm. Des.10(13), 1519–1536 (2004).
   PubMedGoogle Scholar
• Polson JW, McCallion N, Waki H et al. Evidence for cardiovascular autonomic dysfunction in neonates with coarctation of the aorta. Circulation113(24), 2844–2850 (2006).
   PubMedGoogle Scholar
• Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med.311(13), 819–823 (1984).
   PubMed Web of Science ®Google Scholar
• Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J. Am. Coll. Cardiol.23(3), 570–578 (1994).
   PubMed Web of Science ®Google Scholar
• Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol.26(5), 1257–1263 (1995).
   PubMed Web of Science ®Google Scholar
• Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation107(8), 1100–1102 (2003).
   PubMed Web of Science ®Google Scholar
• Leenen FH. Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circ. Res.101(3), 221–223 (2007).
   PubMedGoogle Scholar
• Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol.20(1), 248–254 (1992).
   PubMed Web of Science ®Google Scholar
• Wang H, Huang BS, Ganten D, Leenen FH. Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circ. Res.94(6), 843–849 (2004).
   PubMedGoogle Scholar